Non-invasive early detection of cancer four years before conventional diagnosis using a blood test

Xingdong Chen, Jeffrey Gole, Athurva Gore, Qiye He, Ming Lu, Jun Min, Ziyu Yuan, Xiaorong Yang, Yanfeng Jiang, Tiejun Zhang, Chen Suo, Xiaojie Li, Lei Cheng, Zhenhua Zhang, Hongyu Niu, Zhe Li, Zhen Xie, Han Shi, Xiang Zhang, Min Fan, Xiaofeng Wang, Yajun Yang, Justin Dang, Catie McConnell, Juan Zhang, Jiucun Wang, Shunzhang Yu, Weimin Ye (), Yuan Gao (), Kun Zhang (), Rui Liu () and Li Jin ()
Additional contact information
Xingdong Chen: Fudan University
Jeffrey Gole: Singlera Genomics Inc.
Athurva Gore: Singlera Genomics Inc.
Qiye He: Singlera Genomics (Shanghai) Ltd.
Ming Lu: Fudan University
Jun Min: Singlera Genomics Inc.
Ziyu Yuan: Fudan University
Xiaorong Yang: Fudan University
Yanfeng Jiang: Fudan University
Tiejun Zhang: Fudan University
Chen Suo: Fudan University
Xiaojie Li: Singlera Genomics (Shanghai) Ltd.
Lei Cheng: Singlera Genomics (Shanghai) Ltd.
Zhenhua Zhang: Singlera Genomics (Shanghai) Ltd.
Hongyu Niu: Singlera Genomics (Shanghai) Ltd.
Zhe Li: Singlera Genomics (Shanghai) Ltd.
Zhen Xie: Singlera Genomics (Shanghai) Ltd.
Han Shi: Singlera Genomics Inc.
Xiang Zhang: Taizhou Disease Control and Prevention Center
Min Fan: Taixing Disease Control and Prevention Center
Xiaofeng Wang: Fudan University
Yajun Yang: Fudan University
Justin Dang: Singlera Genomics Inc.
Catie McConnell: Singlera Genomics Inc.
Juan Zhang: Fudan University
Jiucun Wang: Fudan University
Shunzhang Yu: Fudan University
Weimin Ye: Fudan University
Yuan Gao: Singlera Genomics Inc.
Kun Zhang: University of California at San Diego
Rui Liu: Singlera Genomics Inc.
Li Jin: Fudan University

Nature Communications, 2020, vol. 11, issue 1, 1-10

Abstract: Abstract Early detection has the potential to reduce cancer mortality, but an effective screening test must demonstrate asymptomatic cancer detection years before conventional diagnosis in a longitudinal study. In the Taizhou Longitudinal Study (TZL), 123,115 healthy subjects provided plasma samples for long-term storage and were then monitored for cancer occurrence. Here we report the preliminary results of PanSeer, a noninvasive blood test based on circulating tumor DNA methylation, on TZL plasma samples from 605 asymptomatic individuals, 191 of whom were later diagnosed with stomach, esophageal, colorectal, lung or liver cancer within four years of blood draw. We also assay plasma samples from an additional 223 cancer patients, plus 200 primary tumor and normal tissues. We show that PanSeer detects five common types of cancer in 88% (95% CI: 80–93%) of post-diagnosis patients with a specificity of 96% (95% CI: 93–98%), We also demonstrate that PanSeer detects cancer in 95% (95% CI: 89–98%) of asymptomatic individuals who were later diagnosed, though future longitudinal studies are required to confirm this result. These results demonstrate that cancer can be non-invasively detected up to four years before current standard of care.

Date: 2020
References: Add references at CitEc
Citations: View citations in EconPapers (4)

Downloads: (external link)
https://www.nature.com/articles/s41467-020-17316-z Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-17316-z

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-020-17316-z

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().